Complement Receptor Targeted Liposomes Encapsulating the Liver X Receptor Agonist GW3965 Accumulate in and Stabilize Atherosclerotic Plaques
Advanced Healthcare Materials, vol. 9, pp. e2000043
Abstract
Atherosclerosis is characterized by the retention of lipids in foam cells in the arterial intima. The liver X receptor (LXR) agonist GW3965 is a promising therapeutic compound, since it induces reverse cholesterol transport in foam cells. However, hepatic LXR activation increases plasma and liver lipid levels, inhibiting its clinical development. Herein, a formulation that specifically enhances GW3965 deposition in the atherosclerotic lesion is aimed to be developed. GW3965 is encapsulated in liposomes functionalized with the cyclic peptide Lyp-1 (CGNKRTRGC), which binds the p32 receptor expressed on foam cells. These liposomes show preferential uptake by foam cells in vitro and higher accumulation in atherosclerotic plaques in mice compared to non-targeted liposomes as determined by in vivo imaging. Flow cytometry analysis of plaques reveals increased retention of Lyp-1 liposomes in atherosclerotic plaque macrophages compared to controls (p < 0.05). Long term treatment of established plaques in LDLR -/- mice with GW3965-containing Lyp-1 liposomes significantly reduces plaque macrophage content by 50% (p < 0.01). Importantly, GW3965-containing Lyp-1 liposomes do not increase plasma or hepatic lipid content. Thus, GW3965-containing Lyp-1 liposomes successfully target the atherosclerotic macrophages allowing plaque stabilization without commonly observed side effects of LXR agonists.
Authors 9
-
Affiliation as printed
Division BioTherapeutics Leiden Academic Centre for Drug Research Leiden University Leiden 2333CC The Netherlands
Division BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, 2333CC The Netherlands
-
Affiliation as printed
Division BioTherapeutics Leiden Academic Centre for Drug Research Leiden University Leiden 2333CC The Netherlands
Division BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, 2333CC The Netherlands
-
Affiliation as printed
Department of Supramolecular and Biomaterials Chemistry Leiden Institute of Chemistry Leiden University Leiden 2333CC The Netherlands
Department of Supramolecular and Biomaterials Chemistry, Leiden Institute of Chemistry, Leiden University, Leiden, 2333CC The Netherlands
-
Affiliation as printed
Department of Supramolecular and Biomaterials Chemistry Leiden Institute of Chemistry Leiden University Leiden 2333CC The Netherlands
Department of Supramolecular and Biomaterials Chemistry, Leiden Institute of Chemistry, Leiden University, Leiden, 2333CC The Netherlands
-
Affiliation as printed
Division BioTherapeutics Leiden Academic Centre for Drug Research Leiden University Leiden 2333CC The Netherlands
Division BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, 2333CC The Netherlands
-
Affiliation as printed
Division BioTherapeutics Leiden Academic Centre for Drug Research Leiden University Leiden 2333CC The Netherlands
Division BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, 2333CC The Netherlands
-
Affiliation as printed
Division BioTherapeutics Leiden Academic Centre for Drug Research Leiden University Leiden 2333CC The Netherlands
Division BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, 2333CC The Netherlands
-
Affiliation as printed
Division BioTherapeutics Leiden Academic Centre for Drug Research Leiden University Leiden 2333CC The Netherlands
Division BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, 2333CC The Netherlands
-
Affiliation as printed
Division BioTherapeutics Leiden Academic Centre for Drug Research Leiden University Leiden 2333CC The Netherlands
Division BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, 2333CC The Netherlands
Cited by 23 stored of 22
No patents citing this paper on Lens.org (checked 2026-10-11).